- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04228315
Biomarkers of P. Vivax Relapse
January 10, 2020 updated by: Armed Forces Research Institute of Medical Sciences, Thailand
Identification of Hypnozoite Biomarkers and Relapse Patterns of Plasmodium Vivax
Plasmodium vivax malaria is difficult to manage because even after taking medicine that kills the infection in the blood, it can continue to hide quietly in the liver, later re-emerging into the blood and causing another episode of malaria illness (relapse).
This clinical trial aims to enroll patient with P. vivax infections and try to detect signals in blood, urine and/or saliva coming from the silent liver stages to help identify who could benefit from treatment with primaquine.
It also will explore if certain factors of patients negatively impact primaquine efficacy.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Plasmodium vivax, the most widely distributed human malaria, has resisted control largely due to a relapsing hypnozoite liver stage that is clinically silent until emergence and replication in the blood weeks to months later.
Curative treatment with primaquine is often not achieved due to potential toxicity in those with G6PD deficiency, poor adherence to the two-week course, and ineffective metabolism of primaquine in those with polymorphisms in cytochrome P450 isoenzyme 2D6 (CYP2D6).
Identifying those who harbor hypnozoites will allow for judicious use of primaquine in returning travelers/active duty personnel as well as targeted administration to those living in endemic areas to interrupt parasite transmission in the community.
The trial will be conducted in patients presenting with uncomplicated P. vivax malaria at clinical trial sites run by Armed Forces Research Institute of Medical Sciences (AFRIMS) in Southeast Asia.
It is designed to capture vivax patients who still harbor the dormant liver stage hypnozoites after treatment with a short acting oral blood schizonticide, and subsequently relapse during the follow-up period while staying in in study-provided housing to reduce risk of reinfection and surveilled daily for parasites or clinical signs of relapse.
Longitudinal blood and urine sampling will be done to allow for retrospective analysis to identify biomarkers of hypnozoite infection and subsequent relapse using a systems biology approach.
A smaller arm will be enrolled and will receive the short-activing schizonticide with primaquine radical cure at time of admission and followed similarly for relapse.
All subjects will be followed for a total of 6 months in order to assess effectiveness of primaquine radical cure for P. vivax infections.
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Michele D Spring, MD
- Phone Number: 4630 +66(0)2696-2700
- Email: michele.spring.ctr@afrims.org
Study Contact Backup
- Name: Norman Waters, PhD
- Phone Number: +66-(0)81 902 6756
- Email: Norman.Waters.mil@afrims.org
Study Locations
-
-
-
Khun Han, Thailand
- Recruiting
- Khun Han Hospital
-
Contact:
- Ratchadaporn Runcharoen, MD
-
Sub-Investigator:
- Mariusz Wojnarski, MD
-
Sub-Investigator:
- Phimpan Pisutsan, MD
-
Sub-Investigator:
- Norman Waters, PhD
-
Sub-Investigator:
- Jessica Lin, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
For P. vivax-infected malaria subjects
- Are a Thai male or non-pregnant/non-lactating female aged at least 18 years and are able to fluently speak and understand Thai
- Willingness to participate in the study as evidenced by witnessed, signed informed consent from the subject (written or thumb print)
- Have P. vivax malaria mono-infection as determined by blood smear, with a parasitemia range of 100-400,000 parasites/microliter
- Are available to stay in a controlled setting for the first 28 days of this study to minimize exposure to mosquitoes and available for follow-up for anticipated study duration
- Resides in Sisaket or Ubon Ratchathani Province
- Are of normal (non-deficient or >30% activity) G6PD phenotype as defined by WHO
- Agree to not seek outside medical care prior to contacting the Armed Forces Research Institute of Medical Sciences (AFRIMS) study team if a fever develops during study participation (approximately 180 days), unless emergency medical care is required
For healthy control group
- Are a Thai male or non-pregnant/non-lactating female aged at least 18 years and are able to fluently speak and understand Thai
- Willingness to participate in the study as evidenced by witnessed, signed informed consent from the subject (written or thumb print)
- Free of malaria and other significant health problems as established by medical history, laboratory assessment and clinical examination by clinical investigator
- Normal (non-deficient or > 30% activity) G6PD phenotype as defined by World Health Organization (WHO)
- Resides in Sisaket or Ubon Ratchathani Province
Exclusion Criteria:
For P. vivax-infected malaria subjects
- Have an allergic reaction to artesunate or primaquine
- History of anti-malarial drug use within the past 28 days
- Have symptoms of severe malaria needing urgent treatment, such as serious vomiting, unable to eat or drink, prostration, or other signs/symptoms of concern to the doctors
- Are a pregnant or lactating female, or female of childbearing age, up to 50 years of age or otherwise individually assessed for childbearing potential, who does not agree to use an acceptable form of contraception (e.g. pills or injectable) during this study and for 1 month after study completion
- Chronic use of medications known to cause drug interactions with primaquine or CYP450 2D6 (selective serotonin reuptake inhibitors (SSRIs) or other medications used for psychological conditions, as well as antihistamines, antihypertensives, codeine)
- Any other significant finding that in the opinion of the investigator would increase the risk of having an adverse outcome from participating in this study
For healthy control group
- Has history of malaria infection in the past 10 years
- Positive for any Plasmodium species by blood smear or PCR at time of screening
- Pregnant or lactating female
- G6PD deficient as defined by WHO
- Any other significant finding that in the opinion of the investigator would increase the risk of compromising the validity of being a control (eg., chronic daily chewing of betel nut (may impact saliva assays) or menstruating females (whereby urine collections may have blood and impact assay results), etc.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Early primaquine group
Thirty (30) P. vivax-infected adults will be enrolled in Khun Han Hospital to receive 5 days or oral artesunate (4 mg/kg) and 15 mg/day of oral primaquine for 14 days
|
radical cure dosing
|
Active Comparator: Delayed Primaquine group
Sixty (60) P. vivax-infected adults will be enrolled in Khun Han Hospital to receive 5 days or oral artesunate (4 mg/kg) and the primaquine regimen (15 mg/day for 14 days) not given until 42 days after enrollment
|
radical cure dosing
|
No Intervention: Healthy control group
Ten (10) age- and gender-matched controls will be enrolled for one day to obtain biological samples to be compared to the 2 intervention arms
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Therapeutic efficacy of a radical cure course of primaquine for uncomplicated P. vivax infection
Time Frame: 6 months
|
In subjects presenting with uncomplicated P. vivax infection, determine frequency of P. vivax recurrence throughout the study period after being administered a 14-day course of primaquine
|
6 months
|
Build a biorepository of prospectively collected blood and urine samples in P. vivax patients prior to relapse to analyze for hypnozoite biomarkers
Time Frame: 6 months
|
At pre-determined time points, collect biological samples to be processed and stored for proteomic, metabolomic, genomic and transcriptomic markers of latent hypnozoites, allowing for comparisons of markers in those who did and those who did not relapse
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Characterize the patterns of relapsing Southeast Asian P. vivax in infected subjects
Time Frame: 28 days
|
Percentage of P. vivax relapse in subjects with uncomplicated P. vivax mono-infection in the 28 days following treatment with oral blood stage anti-malarial treatment with comparisons between those administered primaquine at enrollment and those who did not receive primaquine
|
28 days
|
Delineate relapse kinetics of P. vivax infection using molecular diagnostic methods,
Time Frame: 42 days
|
At pre-determined time points starting at admission and prior to P. vivax relapse, compare limit of detection of recently emerged erythrocytic forms by blood smear, polymerase chain reaction (PCR) and ultra sensitive PCR
|
42 days
|
Determine percentage of P. vivax isolates resistant to antimalarial drugs used for treatment
Time Frame: 6 months
|
Parasite growth inhibition as measured by concentration at which 50% of growth is inhibited (IC50) to antimalarial drug panel using pLDH ELISA techniques
|
6 months
|
Establish rates of P. vivax relapse versus new infection with vivax using molecular methods
Time Frame: 6 months
|
Perform genome sequencing to determine genetic signatures of the vivax parasite, comparing initial infection with recurrences to identify relapse versus a new infection
|
6 months
|
Characterize the rate glucose 6-phosphate dehydrogenase (G6PD) deficiency of study population
Time Frame: 3 months
|
Incidence of G6PD deficiency (<30% activity) using quantitative spectrophotometry diagnostics
|
3 months
|
Characterize hepatic cytochrome P450 (CYP450) 2D6 enzyme genotypes and predicted phenotypes in this study population
Time Frame: 1 day
|
Genotype CYP450 2D6 alleles in this study population and resultant predicted metabolism phenotypes using Activity Score A (AS-A)
|
1 day
|
Determine primaquine pharmacokinetics in this study population
Time Frame: 56 days
|
Measure plasma concentrations of primaquine and its major metabolites at 0,2,4,8,10 and 24 hours after initial primaquine dose and calculate the area under the curve (AUC) for each subject
|
56 days
|
Determine primaquine pharmacokinetics in this study population
Time Frame: 56 days
|
Measure urine concentrations of primaquine and its major metabolites at 0-4 hours, 4-10 hours and 10-24 hours after initial primaquine dose and calculate the area under the curve (AUC) for each subject
|
56 days
|
Assess impact of risk factors of travel and prior malaria history on P. vivax relapse kinetics
Time Frame: 6 months
|
Determine number of days of travel to high malaria risk areas in 30 days prior to enrollment for each subject to compare with parasite genetic relatedness of initial and recurrent vivax infections
|
6 months
|
Measure rates of gametocyte carriage
Time Frame: 6 months
|
Determine rate and duration of sexual stage infections based on light microscopy and molecular analyses (PCR) from samples drawn at enrollment and pre-determined time points over study period
|
6 months
|
Determine if humoral immunity contributes to protection against P. vivax recurrence
Time Frame: 6 months
|
Measure antibody levels against vivax antigens merozoite surface protein-1 (MSP-1) and circumsporozoite protein (CSP) at Day 0,28,90 and 180 and compare to rate of P. vivax recurrence
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Study Director: Norman Waters, PhD, Armed Forces Research Institute of Medical Sciences, Thailand
- Principal Investigator: Michele Spring, MD, Armed Forces Research Institute of Medical Sciences, Thailand
- Principal Investigator: Ladaporn Bodhidatta, MD, Armed Forces Research Institute of Medical Sciences, Thailand
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 19, 2019
Primary Completion (Anticipated)
June 30, 2021
Study Completion (Anticipated)
December 31, 2024
Study Registration Dates
First Submitted
January 10, 2020
First Submitted That Met QC Criteria
January 10, 2020
First Posted (Actual)
January 14, 2020
Study Record Updates
Last Update Posted (Actual)
January 14, 2020
Last Update Submitted That Met QC Criteria
January 10, 2020
Last Verified
December 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- WR2643
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology; Timika...Completed
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
University of IbadanShin Poong Pharm Co Ltd 161 yoksam-ro, Gangnam-Gu Seoul 135-925, Korea; Institute...CompletedPlasmodium Falciparum Malaria | Uncomplicated Malaria | Malaria FeverNigeria
-
Research Institute for Tropical Medicine, PhilippinesWorld Health OrganizationCompletedTES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014 (TES)Malaria | Vivax Malaria | Falciparum Malaria | Malaria Recrudescence
Clinical Trials on Primaquine
-
University of Mississippi, OxfordCompletedMalariaUnited States
-
University of Mississippi, OxfordCompletedMalaria | Glucose 6 Phosphate Dehydrogenase DeficiencyUnited States
-
University of California, San FranciscoBill and Melinda Gates Foundation; Wellcome Trust; Malaria Research and Training... and other collaboratorsCompleted
-
Menzies School of Health ResearchTribhuvan University, NepalActive, not recruitingMalaria | Malaria, Vivax | Malaria,FalciparumNepal
-
PATHMahidol Oxford Tropical Medicine Research UnitTerminated
-
University of California, San FranciscoPan American Health OrganizationWithdrawnMalaria, Vivax | Relapse
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
Menzies School of Health ResearchArmauer Hansen Research Institute, EthiopiaWithdrawn
-
Menzies School of Health ResearchWorld Health Organization; Walter and Eliza Hall Institute of Medical Research and other collaboratorsUnknown
-
Ulrika MorrisUppsala University; University of California, San Francisco; RTI International; Mahidol Oxford Tropical Medicine Research Unit and other collaboratorsCompletedMalaria | Plasmodium InfectionsTanzania